LuciDabra (Dabrafenib) is a revolutionary kinase inhibitor that targets patients with unresectable or metastatic melanoma harboring the BRAF V600E mutation.

LuciDac 15 mg Tablet

Molecule : DacomitinibManufacturer : Lucius Pharma

Ask for Price

LuciDac 45 mg Tablet

Molecule : DacomitinibManufacturer : Lucius Pharma

Ask for Price

LuciDap 1 mg Tablet

Molecule : DaprodustatManufacturer : Lucius Pharma

Ask for Price

LuciDasa 20 mg Tablet

Molecule : DasatinibManufacturer : Lucius Pharma

Ask for Price

LuciDasa 20 mg tablets contain dasatinib, a BCR-ABL tyrosine kinase inhibitor. It is used for Philadelphia chromosome-positive chronic myeloid leukaemia

LuciDasa 50 mg Tablet

Molecule : DasatinibManufacturer : Lucius Pharma

Ask for Price

LuciDasa 50 mg tablets contain dasatinib, a BCR-ABL tyrosine kinase inhibitor. It is used for Philadelphia chromosome-positive chronic myeloid leukaemia

LuciDasa 70 mg Tablet

Molecule : DasatinibManufacturer : Lucius Pharma

Ask for Price

LuciDela 150 mg Tablet

Molecule : IdelalisibManufacturer : Lucius Pharma

Ask for Price

LuciDeucra 6 mg Tablet

Molecule : DeucravacitinibManufacturer : Lucius Pharma

Ask for Price

LuciDorda 125 mg Capsule

Ask for Price

LuciDorda 125 mg capsules contain dordaviprone, an imipridone (ClpP agonist and DRD2 antagonist). It is used for diffuse midline glioma